Severe belly pain, severe pain in the right shoulder, or dizziness and faintness after a liver biopsy need emergency care. Call 911 or go to the emergency department.
A liver biopsy is the removal of a thread of liver tissue so that it can be examined under a microscope. The sample is narrow, closer to a short length of thread than to anything most people picture when they hear the word biopsy, and it is collected with a hollow needle that cuts and holds a core of tissue as it passes through the organ.
In the laboratory, that core is set in wax, sliced very thinly and stained so different features stand out. A pathologist then reads the liver the way an engineer reads a cross section, checking fat droplets inside cells, swollen or dying cells, inflammatory cells, the small bile ducts, deposits of iron or copper, and fibrous scar tissue laid down between the liver's working units. What makes the sample informative is rarely one feature on its own. It is the pattern, where the damage sits, which structures it spares, and how far through the tissue it has spread.
National guidance written jointly by gastroenterology, radiology and pathology bodies frames the biopsy as a procedure with specific indications, a consent discussion and defined safety checks, not a routine screening test 1. Put simply, it is arranged to answer a question that gentler tests have left open, and the question is agreed before the needle is ever prepared.
A biopsy is needed when its result would change what happens next and no less invasive test can supply that result. Guidance on the use of liver biopsy sets out the common grounds for arranging one, including persistently abnormal liver blood tests with no clear explanation, uncertainty about which of several possible causes is driving liver injury, and the need to know how much scarring has built up 1.
Three situations come up repeatedly. The first is the unexplained pattern, where liver enzymes stay raised for months, scans look unremarkable and the antibody and viral workup has not settled the question. The second is the mixed picture, where two or more processes could be acting at once, for example excess fat in the liver alongside another condition, and the relative contribution of each matters for what a clinician recommends. The third is staging, where the diagnosis is reasonably clear but the amount of fibrosis is not, and that number influences how closely someone is followed.
A biopsy is also considered when the non-invasive tests disagree with each other or with the clinical picture. None of this means a biopsy is automatic. Many people with abnormal liver blood tests never need one, because the cause becomes clear from history, repeat bloods and imaging. The decision belongs to a clinician who knows the whole case, and it is a conversation about what the sample would add, not a default next step.
It can tell you what the liver tissue itself looks like, which is a different kind of information from anything measured in blood or on a scan. Blood tests show enzymes leaking from injured cells and proteins the liver makes. Imaging shows size, texture, fat content and stiffness. Tissue shows the actual cells, so a pathologist can separate fat sitting quietly inside liver cells from fat accompanied by cell injury and inflammation, and can grade how active that injury is while separately staging how much scar tissue has accumulated 2.
That split between grade and stage is the heart of it. Grade describes current activity, how much inflammation and cell damage is happening now. Stage describes accumulated structural change, how much fibrous tissue has been laid down and whether it has started to distort the liver's architecture. Two people can share an identical enzyme result and sit at very different stages.
The sample also carries clues to cause. The distribution of fat, the location of inflammation, changes around the bile ducts and the presence of stored metals all point in particular directions, which is why a biopsy is useful when several explanations are competing.
Its limits are real and well described. A biopsy samples a very small fraction of the organ, and this is associated with some variability in how fibrosis is staged, as well as differences between how two pathologists read the same slide 2. A result is read alongside the rest of the picture, never alone.
ALT is an enzyme that sits inside liver cells and leaks into the blood when those cells are injured, which makes a persistently raised value one of the usual starting points for a liver workup. A single value does not explain why cells are injured and does not show scarring, which is where imaging and, in some cases, tissue come in.
FitScript's optimal range for ALT is 10 to 25 U/L, with 10 to 25 U/L in men and 8 to 19 U/L in women. Your own laboratory's range is the one as printed on your lab report, and the two are not interchangeable. FitScript's optimal ranges are optimization targets, not diagnostic cut-offs. The fuller explanation of what this enzyme measures, how it is tested and how to read a result sits on its own marker page.
In a percutaneous biopsy, a needle is passed through the skin over the liver and a core of tissue is taken in a fraction of a second. It is the route used most of the time, and in most services it is a day case with a planned period of observation afterwards 1.
The sequence is straightforward. Before the day, a clinician checks the blood count and clotting results and reviews anything that affects bleeding. On arrival there is a consent discussion covering why the sample is being taken and what can go wrong. The person lies on their back, usually with the right arm raised above the head, which opens the spaces between the lower ribs. An operator scans the liver with ultrasound and chooses a window where the needle can reach liver tissue without crossing the lung, the gallbladder, large blood vessels or bowel. The skin is cleaned and numbed with local anaesthetic, a tiny nick is made, and the person is asked to hold still and hold their breath at a particular point so the liver stops moving. The needle is advanced and fired, a core is captured, and the needle comes straight back out. Pressure and a dressing follow, and people are often asked to lie on the right side for a while.
A review of ultrasound-guided percutaneous biopsy sets out what operators need to understand for this to go well, including anatomy, needle selection, positioning and the difference between marking a spot in advance and watching the needle in real time 3. Real-time guidance is what allows the path to be checked as it is taken, rather than assumed.
The transjugular route is used when passing a needle through the skin and liver capsule carries too much bleeding risk, because clotting is impaired, platelets are low, or there is a large amount of fluid in the abdomen. A systematic review of the technique describes exactly these situations as its main indications 4.
The logic is elegant. Instead of entering the liver from outside, the operator numbs the skin over a vein in the neck, passes a thin catheter down through the large veins into the hepatic veins that drain the liver, and takes the sample from inside the vein outwards. Any bleeding from the needle track drains back into the venous system rather than into the abdominal cavity, which is why the route suits people whose blood does not clot normally. The procedure is done in an imaging suite with X-ray guidance, and pressures inside the hepatic veins can be measured during the same sitting, which is sometimes the reason the route is chosen in the first place.
Studies indicate that the transjugular approach achieves a usable sample in the great majority of attempts and that serious complications are uncommon, although the cores tend to be smaller or more fragmented than those taken through the skin 4. Operators often take more than one pass to compensate.
An endoscopic ultrasound-guided biopsy takes the sample from inside the digestive tract. A flexible endoscope with an ultrasound probe at its tip is passed through the mouth into the stomach and duodenum, the liver is imaged from that vantage point through the wall of the gut, and a needle is advanced across the wall into liver tissue under direct ultrasound vision. Because the left and right lobes sit at different angles from the stomach and duodenum, both can often be sampled in one sitting.
This route involves sedation and an endoscopy service, so it is not a like-for-like replacement for a skin-puncture biopsy in every setting. It becomes attractive when someone is already scheduled for an upper endoscopy for another reason, when body habitus makes the percutaneous window awkward, or when a service has the expertise readily available.
Research suggests the endoscopic and percutaneous routes deliver broadly comparable amounts of usable tissue, based on a systematic review and meta-analysis of randomised controlled trials that compared them directly 5. Which one is offered depends on local services, the reason for the sample and the individual's anatomy and clotting, and that choice is made by the team arranging the procedure rather than by the person requesting a particular route.
They differ in how the needle reaches the liver, who they suit and what else they can do in the same sitting. The table below summarises the practical differences described in the guidance and reviews for each route 1, 3, 4, 5.
| Route | How the sample is reached | Often considered when | Practical points |
|---|---|---|---|
| Percutaneous | Needle through the skin over the liver, usually with ultrasound guidance and local anaesthetic | Clotting and platelet results are acceptable and there is no large collection of abdominal fluid | Usually a day case with a set observation period; pain and bleeding are the described risks |
| Transjugular | Catheter from a neck vein into the hepatic veins, sampling from inside the vein outwards | Clotting is impaired, platelets are low, or there is significant abdominal fluid | Done in an imaging suite; hepatic vein pressures can be measured at the same time; cores may be smaller or fragmented |
| Endoscopic ultrasound-guided | Needle from inside the stomach or duodenum under ultrasound from the endoscope tip | An upper endoscopy is already planned, or the skin route is technically awkward | Requires sedation and an endoscopy service; both lobes can often be sampled |
None of these is universally better. The route is matched to the person, and the reasoning should be explained before consent is given.
Preparation centres on bleeding risk, fasting instructions and consent. Guidance describes checking the blood count and clotting before the procedure and discussing the risks as part of consent 1. Some medicines affect bleeding and may need to be paused beforehand. Ask your prescriber well in advance, and do not stop anything on your own.
The unit gives its own instructions about eating and drinking, what time to arrive and whether sedation will be offered. If sedation is planned, someone needs to take you home and stay with you, and driving is off the table for the rest of the day. Bring a current list of everything you take, including anything bought over the counter.
During a percutaneous biopsy most people feel pressure and a push rather than a sharp pain, because the skin and the tissue beneath it have been numbed, though the liver capsule itself can produce a brief ache. Afterwards there is a period of monitoring, with pulse and blood pressure checked at intervals set by the unit. Timing varies between services, so ask what to expect rather than planning around a fixed number.
Afterwards, pain around the biopsy site or spreading to the right shoulder is described following percutaneous biopsy and should be reported to the team rather than sat out at home 1. Heavy lifting and strenuous activity are usually restricted for a period the unit specifies. Ask when and how the pathology result will be given to you.
The main risks are pain and bleeding. Guidance on the use of liver biopsy identifies pain as the complication reported most frequently after the percutaneous route, and bleeding as the serious complication that drives most of the safety precautions around the procedure 1.
Bleeding can show up as pain, lightheadedness, a racing pulse or a falling blood pressure, which is why monitoring continues after the needle is out. For the transjugular route, a systematic review reports a low overall complication rate, with problems at the neck entry point and transient discomfort among those described 4.
There are also outcomes that are not complications but still matter. A sample can come back too small or too fragmented to answer the question, and a result can be equivocal, leaving the clinical picture much as it was.
Severe abdominal pain, severe right shoulder pain, dizziness or faintness, breathlessness, fever or chills after a biopsy need emergency care. Call 911 or go to the emergency department. Do not wait to see whether the feeling passes, and do not substitute a routine appointment for these signs.
Adequacy is judged by how much readable liver is in the core, not by how the procedure felt. Pathologists assess the length of the core, how fragmented it is and how many complete portal tracts it contains, because fibrosis staging depends on seeing enough of the liver's repeating structural units to judge how the architecture has changed 1.
This is also why route matters. Transjugular cores are often smaller or come in pieces, and operators commonly take several passes so the pathologist has enough material to work with 4. A short or crumbling sample can under-call scarring, because scar tissue is distributed unevenly and a small core may land in a quieter patch.
The same issue explains the known ceiling on biopsy accuracy. Sampling a very small portion of a large organ is associated with variability in staging, and two experienced readers can grade the same slide slightly differently 2. That is not a reason to distrust a report. It is a reason to read a biopsy result as one strong input alongside blood tests, imaging and the clinical story, and to ask what the pathologist noted about sample quality when a result looks surprising. If the sample is inadequate, a clinician weighs repeating it against using non-invasive tests to follow the question over time.
It is used for conditions where the distinction between activity and scarring, or between competing causes, changes management. In fatty liver disease, a biopsy is the reference against which other tests are measured, because it separates fat alone from fat accompanied by inflammation and cell injury, and it stages fibrosis at the same time 2.
In alcohol-related liver disease, a biopsy can confirm the pattern of injury and establish how much scarring has developed, which is particularly useful when more than one cause of liver injury may be present at once 6.
In primary biliary cholangitis, a biopsy is not required to make the diagnosis in people with the characteristic antibody and cholestatic blood test pattern, and it is reserved for uncertainty, for suspected overlap with another condition, or where staging would alter follow-up 7. That is a good illustration of the general principle. As non-invasive testing has improved, the biopsy has moved from a routine step towards a targeted one, used where the tissue answers something the rest of the workup cannot.
Across all of these, the biopsy describes the liver. It does not decide what happens next on its own, and any resulting management belongs to the clinician who ordered it.
For the specific job of estimating how much scarring there is, non-invasive testing now does a great deal of the work. Transient elastography measures how stiff the liver is by timing a mechanical pulse as it travels through tissue, and stiffer tissue generally reflects more fibrosis. Research suggests that, in primary biliary cholangitis, transient elastography identifies advanced fibrosis with good accuracy when compared against biopsy as the reference, based on a systematic review and meta-analysis of the two tests 8.
Stiffness measurement has practical limits. Results can be affected by factors other than scarring, such as marked inflammation or congestion, and readings can be unreliable in some body shapes. Blood-based fibrosis scores built from routine results add another layer and are useful for sorting low risk from higher risk, but they are estimates rather than pictures of tissue.
What these tests do not do is grade the activity of injury or separate fat alone from fat with inflammation and cell damage, which is one of the standing reasons tissue is still requested in fatty liver disease 2. The practical position in 2026 is layered. Non-invasive tests come first and resolve most questions about scarring. A biopsy is kept for the cases where those tests conflict, where the clinical picture does not fit, or where the exact pattern inside the tissue would change the plan.
The tests that shape a biopsy decision are the ones that describe liver injury, liver function and bleeding risk together. Enzyme markers such as ALT, AST, alkaline phosphatase and GGT describe the pattern of injury and whether it looks more hepatocellular or more cholestatic. Bilirubin and albumin speak to how the liver is functioning. Platelet count and clotting results matter twice over, once as indirect signals of advanced liver disease and once as the safety checks that determine which biopsy route is appropriate 1.
Around that core sit the tests that search for a cause, including viral markers, autoantibodies, iron and copper tests, and metabolic markers such as fasting glucose, HbA1c and a lipid panel, since metabolic health and liver fat travel together. A fuller walkthrough of the standard panel is in this guide on what do liver function tests show.
Tracking these over time is more informative than any single draw, because the trend separates a one-off blip from a persistent pattern. FitScript's membership covers 150+ biomarkers tested per year, and Atlas, FitScript's AI health advisor, interprets those results in context so the picture builds rather than resets at each visit.
Talk to a clinician whenever liver blood tests fall outside the range as printed on your lab report, and talk to one promptly when the values stay outside that range on a repeat draw or when symptoms accompany them. The useful framing is observation, then meaning, then next step. The observation is the number and the pattern across markers. The possible meaning is a shortlist of explanations, which may include metabolic factors, alcohol intake, some medicines, infections or inherited conditions. Ask your prescriber about anything you take before assuming a medicine is or is not involved. The next step is a conversation about which further tests, if any, would change the plan.
Before a biopsy, reasonable questions include what the sample is expected to show, how the result would change management, which route is being proposed and why, and what happens if the sample turns out to be inadequate. After one, ask when results will be available and who will go through them with you.
Seek emergency care for severe abdominal pain, severe right shoulder pain, dizziness, faintness, breathlessness, fever or chills after a biopsy. Call 911 or go to the emergency department. This article is educational and not medical advice. Discuss your own results and any treatment with a clinician or licensed provider, who decides what is appropriate for you.
The sampling itself is extremely quick, often over within seconds of the needle being fired. The visit is much longer than the procedure, because it includes checks beforehand and a monitoring period afterwards. Ask your unit how long it expects you to stay, since that varies between services.
For a percutaneous biopsy through the skin, most people are awake with the area numbed by local anaesthetic. Sedation may be offered depending on the route and the service, and an endoscopic ultrasound-guided biopsy involves sedation. The team arranging the procedure decides what is appropriate and will explain it before you consent.
People commonly describe pressure and a brief push rather than a sharp pain, because the skin and tissue beneath it are numbed first. Some feel an ache at the site or in the right shoulder afterwards. Tell the team about any pain rather than waiting it out, and seek emergency care for severe pain by calling 911 or going to the emergency department.
Some medicines affect bleeding and may need to be paused before the procedure. Ask your prescriber well in advance and follow their instructions, and do not stop anything on your own. Bring a full list of everything you take, including anything bought without a prescription.
Timing depends on the laboratory and the hospital, so there is no single answer. The tissue has to be processed, sliced and stained before a pathologist can read it. Ask the team who took the sample when the report is expected and who will go through it with you.
For estimating how much scarring there is, non-invasive tests such as liver stiffness measurement and blood-based scores now answer many questions without tissue. They do not grade how active the injury is or show the detailed pattern inside the cells. A clinician decides when tissue would add something those tests cannot.
Severe abdominal pain, severe right shoulder pain, dizziness, faintness, breathlessness, fever or chills after a biopsy need emergency care. Call 911 or go to the emergency department for any of these. Follow the unit's instructions on rest, lifting and driving, and contact the team with any question about your recovery.
Not automatically. A result outside the range printed on your lab report is a prompt to repeat the test and look for an explanation, not a referral for tissue sampling. A biopsy is considered only when the answer would change what happens next, and that judgement belongs to a clinician who knows your full picture.